核心结合因子白血病劫持易向T细胞分化的PU.1反义启动子
研究揭示RUNX转录因子驱动的PU.1内含子3反义启动子可被CBF融合蛋白RUNX1-ETO和CBFβ-MYH11激活,导致正义/反义转录失衡和髓系分化阻滞;CBF-AML患者反义/正义转录本及启动子可及性比值升高,提示该比值可作为标志物,并揭示治疗新靶点。
要点
- CBF融合蛋白激活PU.1反义启动子,导致正义转录下降和髓系分化阻滞。
- CBF-AML患者反义/正义转录本及启动子可及性比值升高,区别于正常核型AML和健康CD34+细胞。
- 增强子与近端或反义启动子的竞争性互作构成髓系与T细胞发育的二元开关。
核心结论
- CBF白血病融合蛋白通过激活PU.1反义启动子,劫持T细胞生理性机制来降低PU.1正义转录,导致髓系分化阻滞。
研究设计与样本
- 研究采用实验模型和患者样本,比较CBF-AML、正常核型AML和健康CD34+细胞中PU.1反义/正义转录及启动子可及性。
主要发现
- RUNX1-ETO和CBFβ-MYH11分别激活PU.1内含子3的反义启动子,驱动非编码反义转录。
- CBF-AML患者反义/正义转录本比值和启动子可及性比值升高,区别于正常核型AML或健康CD34+细胞。
- 增强子与近端或反义启动子的竞争性互作形成髓系或T细胞发育的二元开关。
关键数值与推荐
- CBF-AML患者反义/正义转录本及启动子可及性比值升高,可作为区别于正常核型AML或健康CD34+细胞的标志。
临床怎么用
- 反义/正义转录本及启动子可及性比值有望作为CBF-AML的识别标志。
- 该机制为精准靶向癌基因诱导的染色质重塑提供潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is PU.1. Reduced levels of PU.1 are characteristic for human acute myeloid leukemia (AML) and are known to induce AML in mouse models. Here, we show that transcriptional downregulation of PU.1 is an active process involving an alternative promoter in intron 3 that is induced by RUNX transcription factors driving noncoding antisense transcription. Core-binding factor (CBF) fusions RUNX1-ETO and CBFβ-MYH11 in t(8;21) and inv(16) AML, respectively, activate the PU.1 antisense promoter that results in a shift from sense toward antisense transcription and myeloid differentiation blockade. In patients with CBF-AML, we found that an elevated antisense/sense transcript and promoter accessibility ratio represents a hallmark compared with normal karyotype AML or healthy CD34+ cells. Competitive interaction of an enhancer with the proximal or the antisense promoter forms a binary on/off switch for either myeloid or T-cell development. Leukemic CBF fusions thus use a physiological mechanism used by T cells to decrease sense transcription. Our study is the first example of a sense/antisense promoter competition as a crucial functional switch for gene expression perturbation by oncogenes. Hence, this disease mechanism reveals a previously unknown Achilles heel for future precise therapeutic targeting of oncogene-induced chromatin remodeling.
引用
- van der Kouwe E, Heller G, Czibere A, et al. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. Blood. 2021. PMID: 34010414. doi:10.1182/blood.2020008971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。